Craig B Reeder

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Novel therapeutic agents for B-cell lymphoma: developing rational combinations
    Craig B Reeder
    Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 117:1453-62. 2011
  2. pmc Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
    C B Reeder
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leukemia 23:1337-41. 2009
  3. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
  4. pmc Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4860-7. 2012
  5. doi request reprint A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Meaghan L Khan
    Hematology Oncology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Br J Haematol 156:326-33. 2012
  6. pmc Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    Joseph R Mikhael
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 119:4391-4. 2012
  7. pmc Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
  8. ncbi request reprint AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
    Aneel Paulus
    Department of Cancer Biology, Mayo Clinic, Jacksonville, USA
    Br J Haematol 164:352-65. 2014
  9. ncbi request reprint Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
    James L Slack
    Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
    Biol Blood Marrow Transplant 19:1167-74. 2013
  10. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010

Collaborators

Detail Information

Publications17

  1. doi request reprint Novel therapeutic agents for B-cell lymphoma: developing rational combinations
    Craig B Reeder
    Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 117:1453-62. 2011
    ....
  2. pmc Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
    C B Reeder
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leukemia 23:1337-41. 2009
    ..In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed MM with manageable toxicity...
  3. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
    ..This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial...
  4. pmc Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4860-7. 2012
    ..The trial was registered at www.clinicaltrials.gov (NCT00564889)...
  5. doi request reprint A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Meaghan L Khan
    Hematology Oncology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Br J Haematol 156:326-33. 2012
    ..In conclusion, CyBorD demonstrated superior responses and less frequent serious toxicity but more neuropathy when compared to RD and CRD. Importantly, 80% of patients treated with modern therapeutic approaches are alive at 4years...
  6. pmc Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    Joseph R Mikhael
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 119:4391-4. 2012
    ..It is well tolerated with few side effects. CyBorD warrants continued investigation as treatment for AL...
  7. pmc Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
    ..CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy...
  8. ncbi request reprint AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
    Aneel Paulus
    Department of Cancer Biology, Mayo Clinic, Jacksonville, USA
    Br J Haematol 164:352-65. 2014
    ..In summary, we describe for the first time the cellular and molecular events associated with the use of AT-101 in combination with lenalidomide/dexamethasone in preclinical models of plasma cell malignancy. ..
  9. ncbi request reprint Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
    James L Slack
    Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
    Biol Blood Marrow Transplant 19:1167-74. 2013
    ..We conclude that FBM-A is an effective and safe conditioning regimen for adults up to age 69 with hematologic malignancies who have low-, intermediate-, or high-risk scores according to the DRI. ..
  10. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  11. pmc Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1074-80. 2008
    ..3 months (95% CI: 5.3-14.0), the median event-free survival (EFS) was 5.3 months (95% CI: 3.9-11.0), and the median overall survival was 30.5 months (95% CI: 17.8-60.6). We conclude that rituximab can be safely added to standard DHAP...
  12. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  13. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  14. doi request reprint Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase
    Chad Cherington
    Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leuk Res 36:1147-51. 2012
    ..We conclude that MPN-BP can be cured by allo-SCT in a significant percentage of patients, but that adequate leukemic clearance prior to allo-SCT offers an optimal outcome...
  15. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  16. ncbi request reprint Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide
    Ying S Zou
    Cytogenetics and Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 31:1185-9. 2007
    ..FISH did not detect anomalies other than deletion 5q in 31 patients. This study suggests FISH is useful to detect deletion 5q, but is not a substitute for conventional cytogenetics...
  17. ncbi request reprint Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma
    Roshini S Abraham
    Division of Clinical Biochemistry and Immunology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Clin Chem 48:1805-11. 2002
    ..Usually, these light chains exist as monomeric or dimeric forms, but rarely, larger molecules, such as tetramers, have been reported in the serum...